A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight
Latest Information Update: 13 Jan 2026
At a glance
- Drugs Orforglipron (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms ADVANCE
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Jan 2025 Status changed from not yet recruiting to recruiting.
- 08 Nov 2024 New trial record